AliveDx’s Post

Discover more about systemic mastocytosis with our latest resource, developed in collaboration with Medscape Oncology. Explore the in-depth guide, 'Just an Allergy or Could It Be Systemic Mastocytosis?' to understand the complexities behind the symptoms.

Just published March 28, 2024: for experts in #Allergenimmunotherapy in: #CEA Clinical& Experimental Allergy/Early View (open access) https://lnkd.in/ebarhtzE >Efficacy of 300 IR house dust mite immunotherapy as a function of disease activity: Tertile analysis in clinical trials< Thanks to my coauthors Philippe Devillier Pascal Demoly Catherine Gentil Karl-Christian Bergmann Thomas Casale Yoshitaka okamoto KEY MESSAGES: 1) The efficacy of the 300 IR HDM SLIT-tablet was evaluated by tertile analysis in 3 RCTs. 2) Treatment efficacy increased with the placebo score in each tertile, regardless of RCT and combined score. 3) 300 IR HDM SLIT-tablet was associated with greater efficacy in the tertile, showing the highest disease activity. As always: read, learn, enjoy, share! Thank you, Oliver #Rhinitis #housedustmite #allergen #allergenimmunotherapy #hayfever #asthma #SLIT #Immunotherapy #MCID #clinicaltrial

Low Dose Naltrexone (LDN) is a versatile treatment used for various autoimmune diseases and cancer. Many physicians are also finding success with LDN in treating Autism, Hay Fever/Severe Allergy, and Thyroid Disease. Within a specific dosage window, opioid antagonists like naltrexone can exert a “paradoxical” analgesic effect. LDN is considered a prime example of a new class of therapeutic agents known as glial cell modulators. At NP Labs, we offer LDN in multiple convenient forms to suit your needs: 1. Liquid 2. Capsules 3. Sublingual Drops 4. Cream For further details, feel free to reach out to us at: contact@nplabs.online #LDN #AutoimmuneDisease #CancerTreatment #ChronicPain #Autism #AllergyRelief #ThyroidDisease #PharmacyCare #nplabs

In this episode of "Lab Medicine Rounds," learn about oral immunotherapy options for asthma and allergy from Douglas McMahon, M.D., from the Allergy and Asthma Center of Minnesota. Listen now. https://bit.ly/4cE0fK8

Immune signatures predict response to house dust mite subcutaneous immunotherapy in patients with allergic rhinitis. First author: Nan Wang; corresponding authors: Yin Yao, Zheng Liu Read the article here: doi.org/10.1111/all.16068 In allergic #rhinitis (AR) patients undergoing house dust mite subcutaneous immunotherapy (HDM SCIT), distinct clinical and immune features are observed between responders and nonresponders prior to treatment. A model with a combination of baseline sIgE/tIgE ratio, TFR/TFH2 cell ratio, and CD23+ BSM frequency exhibits a strong predictive value for SCIT efficacy, as evidenced by a 12-month posttreatment assessment. The efficacy of this model is validated in an independent cohort. #Allergy_journal Read more articles published in Allergy on #immunotherapy here: https://lnkd.in/dVsjXuR8 https://lnkd.in/gXSmW89Y is a link to the April issue table of contents.

Breathe easy with the latest in allergy and immunology at #ACAAI24 in Boston. Try out our FREE clinical trial monitoring tool, providing customized trial updates directly to your email. Learn more here: https://ctgov.pro/ #ACAAI #AmericanCollegeofAllergyAsthmaAndImmunology #AAAAI

The EVEREST study published in the Journal of Asthma and Allergy, “Disease Burden and Access to Biologic Therapy in Patients with Severe Asthma, 2017–2022: An Analysis of the International Severe Asthma Registry”, has shed light on the significant global disease burden faced by patients suffering from severe asthma, including those without access to biologic therapies, those who were eligible but did not receive these treatments, and T2-targeted biologic recipients. The findings underscore the urgent need for improved healthcare resource utilization, increased access to biologics, and ongoing research on new treatment options to address the unmet needs of patients with severe asthma. Read the full press release: https://lnkd.in/g93bnptj Read the full article here: https://lnkd.in/gXYdYMS3 #ResearchInRealLife #SevereAsthma #Asthma #Research

Many people enjoy the cool weather and colorful foliage autumn brings. But for those with fall allergies, the season also comes with watery eyes, itchy throats, and stuffy noses. Fortunately, there are ways to alleviate these symptoms and appreciate the change of season. In this Q&A, Rachel L. Miller, MD, Chief, Division of Clinical Immunology, and The Dr. David and Dorothy Merksamer Professor of Medicine (#Allergy and #Immunology), Icahn School of Medicine at Mount Sinai, explains what could be triggering your fall allergies and how to treat them. Learn more: https://bit.ly/3ZCllVC

Garden State Allergy & Ashtma Center Better understanding of childhood asthma, towards primary prevention – are we there yet? Consideration of pertinent literature Asthma is a chronic disease, characterized by reversible airway obstruction, airway inflammation and hyper-reactivity. The prevalence of asthma has risen dramatically over the past decade, affecting around 300,000,000 people. The etiology is multifactorial, with genetic, epigenetic, developmental and environmental factors playing a role. A complex interaction between the intrauterine environment, the developing immune system, the infant's microbiome and infectious organisms may lead to the development of allergic sensitization and asthma. Thus, a large number of studies have investigated the risk factors for childhood asthma, with a meticulous search of modifiable factors that could aid in primary prevention.

I congratulate David E. Melon, MD, FACS ‘s thesis acceptance and publication in this month’s Laryngoscope highlighting our private practice’s effort to apply patient journey mapping and care coordination strategies within allergy immunotherapy treatment for chronic disease management of inhalant allergies. https://lnkd.in/eB-8EHzU Core in the study’s finding was the ability to achieve robust high frequency patient engagement data capture achieving survey response rates of over 80% within the collection of over 61,000 survey questions within the study period. The application of electronic health survey instruments, patient reported outcomes, and other measures must have relevance to the patient’s own clinical care goals in order to achieve meaningful response rates for analytical power in future care coordination and patient journey strategies. Automated survey distribution and triggered clinical engagement points driven by patient responses relating to the care they are receiving will be key for successful chronic disease management within future value based care clinical pathways. #patientexpeience #patientjourneymapping #chronicdisease #valuebasedcare #carecoordination